Abstract
Introduction
Little information is available on state-specific financial burdens of diabetes in the Medicaid population, yet such information is essential for state Medicaid programs to plan diabetes care and evaluate the benefits of diabetes prevention. We estimated medical expenditures associated with diabetes among adult Medicaid enrollees in 8 states.
Methods
We analyzed the latest available 2012 CMS Medicaid claims data for 1,193,811 adult enrollees aged 19–64 years in 8 states: Alabama, California, Connecticut, Florida, Illinois, Iowa, New York, and Oklahoma. For each state, we stratified the study population by Medicaid eligibility criteria: disability and nondisability. For each group, we estimated per capita annual medical expenditures on outpatient care, inpatient care, and prescription drugs by using a 2-part model, adjusted for age, sex, race/ethnicity, and comorbidities. We calculated the expenditures associated with diabetes as the difference in predicted expenditures for enrollees with and without diabetes. Analyses were done in 2017.
Results
For disability-based enrollees, the estimated total per capita annual diabetes expenditures ranged from $6,183 in Alabama to $15,319 in New York (all P < .001). For nondisability-based enrollees, the corresponding estimates ranged from $4,985 in Alabama to $15,366 in New York (all P < .001). The proportion of individual components varied by state and eligibility criteria.
Conclusion
Medical expenditures associated with diabetes among adults on Medicaid were substantial and varied across studied states. Our estimates can be used by the 8 state Medicaid programs to prepare health care resources needed for diabetes care and assess the financial benefits of diabetes prevention programs.
Introduction
As a program jointly funded by the federal government and the states, Medicaid plays an important role in providing health care coverage for adults (about 12.9 million low-income adults and 9.8 million disabled adults in 2012) (1). Medicaid is especially important for those with diabetes, as the disease affects low-income individuals disproportionately, and individuals living in poverty are more likely to develop diabetes-related complications (2,3). In 2012, about 14% of adults aged under 65 years, covered by Medicaid, had diabetes (4).
The financial burden imposed on Medicaid programs by diabetes is substantial; in 2013, medical expenditures associated with diabetes paid by Medicaid programs was estimated to be $25.7 billion (5). Medical spending on the Medicaid population is expected to rise in the future because of increases in 1) the number of people with diabetes enrolled in Medicaid programs, resulting from the growing prevalence of people with diabetes (6), expansion of Medicaid programs (7), or both, and 2) per capita medical expenditures associated with diabetes. Per capita medical spending associated with diabetes has been increasing over time (8), and the trend is expected to continue in the foreseeable future (9).
Prior studies on medical expenditures associated with diabetes mainly focused on national-level estimates (3,7). Using data from the Medical Expenditure Panel Survey, Garfield and colleagues calculated that in 2008 nationally, Medicaid spent an average of $9,401 more (more than 3 times higher) on adult enrollees with diabetes than those without diabetes (7). However, as Medicaid eligibility criteria and coverage policies vary greatly by state, these estimates do not reflect expenditures at the state level. The Kaiser Family Foundation estimated that, in 2011, the average annual medical spending per Medicaid enrollee varied from a low of $4,010 in Nevada to a high of $11,091 in Massachusetts (10). In addition, previously reported national estimates did not consider variations in medical expenditures by age group and Medicaid eligibility criteria. Based on the same study by the Kaiser Family Foundation, per capita annual medical spending for children and nondisabled adults was substantially lower ($2,492 and $4,141, respectively) than for older adults and disabled adults ($17,522 and $18,518, respectively) (10).
To plan heath care resources needed for diabetes care and assess the financial benefits of prevention and management programs, decision makers at state Medicaid programs need estimates that reflect the actual expenditure in their states. To that end, we estimated the medical expenditures associated with diabetes among Medicaid adult enrollees aged 19–64 years by disability-based eligibility status (ie, disabled or nondisabled) in 8 states using state-specific data.
Methods
Data
We analyzed Medicaid administrative claims data, also known as Medicaid Analytic eXtract (MAX) files, from the Chronic Conditions Data Warehouse (CCW) of the Centers for Medicare and Medicaid Services (CMS), which includes 100% of fee-for-service (FFS) enrollees. The MAX files were compiled from the Medicaid Statistical Information System at the state level. The files contain annual Medicaid enrollment information, medical utilization claims, and expenditure of services for Medicaid enrollees at the individual level in all 50 states and the District of Columbia (11). All health care service claims, expenditures, and enrollment information were linked through encrypted beneficiary identifiers (11).
Study population
Our study population included 1,193,811 adult Medicaid enrollees aged 19–64 years who were enrolled in an FFS plan for the whole calendar year 2012, the latest available data at the time of the study. For each state, we created 2 subgroups based on enrollees’ disability or nondisability status, using the basis of eligibility indicators in the MAX personal summary file. In each group, enrollees were identified with diagnosed diabetes if they had at least 1 inpatient or 2 outpatient claims 30 days apart based on a primary or secondary diagnosis of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for diabetes (250x, 357.2x, 362.0x, 366.41) (12).
-
The following enrollees were excluded.
Those with restricted benefits, such as benefits for pregnancy-related services only, for family planning services only, and for benefits based on dual eligibility status (eligible for both Medicare and Medicaid) (13).
Those without demographic information (age, sex, race/ethnicity).
Pregnant women, because they have different medical or treatment needs.
Those in long-term care facilities, because diagnosis codes reflected patients’ diagnoses at admission to the facility. Their health care utilizations are therefore not fully captured (11).
States with data anomalies, such as states that did not provide data as required by CMS (13).
Selection of states
To ensure a reliable estimate for each of the medical expenditure components (inpatient care, outpatient care, and prescription drug expenditures), we set a minimum analytical sample size of 1,000 for each of the study groups, based on Medicaid eligibility criteria and diabetes status. There were 2 eligibility criteria for Medicaid enrollees: disability-based and nondisability-based. Combining these eligibility criteria with diabetes status yielded 4 study groups: people with diabetes and disability, people without diabetes but with disability, people with diabetes but without disability, and people without diabetes and without disability. Only 7 states (Alabama, California, Connecticut, Florida, Illinois, New York, and Oklahoma) had analytical sample sizes of more than 1,000 enrollees for all 4 groups. In addition, we included Iowa although the nondisability and diabetes group had only 935 enrollees (Table 1).
Table 1. Characteristics and Unadjusted Total Medical Expenditures of Adult Medicaid Enrollees Aged 19–64 Years by Disability-Based Eligibility and Diabetes Status, 8 States, 2012.
| State and Variable | With disability |
P valuea | Without disability |
P valuea | ||
|---|---|---|---|---|---|---|
| With diabetes | Without diabetes | With diabetes | Without diabetes | |||
| Alabama | ||||||
| Sample size, N | 11,784 | 52,461 | – | 1,365 | 17,137 | – |
| Mean age, y | 51.1 | 42.4 | <.01 | 39.2 | 32.8 | <.01 |
| Female, % | 70.6 | 53.3 | <.01 | 89.7 | 88.1 | .08 |
| Race/ethnicity, % | ||||||
| White | 45.6 | 48.1 | <.01 | 42.9 | 48.4 | <.01 |
| Black | 53.4 | 50.8 | <.01 | 55.7 | 50.0 | <.01 |
| Hispanic | 0.5 | 0.5 | .97 | 1.0 | 0.9 | .68 |
| Other | 0.5 | 0.6 | .11 | 0.4 | 0.6 | .42 |
| Comorbidityb, % | ||||||
| Dementia | 0.4 | 0.2 | <.01 | 0.1 | 0.1 | .83 |
| Chronic pulmonary disease | 32.0 | 21.0 | <.01 | 23.9 | 15.6 | <.01 |
| Rheumatic disease | 2.6 | 2.2 | <.01 | 2.9 | 1.4 | <.01 |
| Peptic ulcer disease | 1.7 | 1.0 | <.01 | 1.6 | 0.9 | .01 |
| Hemiplegia | 0.6 | 0.8 | .06 | 0.3 | 0.1 | .03 |
| Any malignancy | 8.8 | 4.6 | <.01 | 7.5 | 4.2 | <.01 |
| Mild liver disease | 1.7 | 1.0 | <.01 | 0.4 | 0.2 | .01 |
| Moderate/severe liver disease | 0.7 | 0.4 | < .01 | 0.4 | 0.2 | .01 |
| Metastatic tumor | 0.7 | 0.6 | .67 | 1.2 | 0.6 | <.01 |
| AIDS | 0.8 | 1.4 | <.001 | 0.5 | 0.4 | .49 |
| Per capita medical expendituresc, $ | 13,424 | 7,794 | <.01 | 8,069 | 3,747 | <.01 |
| California | ||||||
| Sample, N | 5,619 | 44,703 | – | 3,505 | 99,848 | – |
| Mean age, y | 53.1 | 42.2 | <.01 | 46.5 | 33.9 | <.01 |
| Female, % | 60.2 | 49.1 | <.01 | 67.8 | 63.9 | <.01 |
| Race/ethnicity, % | ||||||
| White | 61.8 | 66.6 | <.01 | 31.8 | 42.1 | <.01 |
| Black | 5.2 | 8.8 | <.01 | 3.6 | 6.0 | <.01 |
| Hispanic | 22.6 | 16.4 | <.01 | 52.4 | 39.6 | <.01 |
| Other | 10.4 | 8.2 | <.01 | 12.2 | 12.2 | .95 |
| Comorbidityb, % | ||||||
| Dementia | 0.3 | 0.2 | <.01 | 0.0 | 0.0 | .65 |
| Chronic pulmonary disease | 28.5 | 15.2 | <.01 | 12.1 | 6.2 | <.01 |
| Rheumatic disease | 3.0 | 1.8 | <.01 | 1.7 | 0.5 | <.01 |
| Peptic ulcer disease | 1.6 | 0.7 | <.01 | 0.6 | 0.3 | <.01 |
| Hemiplegia | 1.1 | 1.0 | .23 | 0.3 | 0.1 | <.01 |
| Any malignancy | 6.9 | 4.0 | <.01 | 15.6 | 3.8 | <.01 |
| Mild liver disease | 4.0 | 1.7 | <.01 | 1.1 | 0.2 | <.01 |
| Moderate/severe liver disease | 2.3 | 0.8 | <.01 | 0.5 | 0.1 | <.01 |
| Metastatic tumor | 1.3 | 1.0 | .03 | 2.1 | 0.6 | <.01 |
| AIDS | 0.9 | 1.0 | .36 | 0.1 | 0.1 | .60 |
| Per capita medical expendituresc, $ | 28,350 | 16,417 | <.01 | 10,857 | 2,315 | <.01 |
| Connecticut | ||||||
| Sample, N | 4,409 | 17,895 | – | 8,530 | 147,690 | – |
| Mean age, y | 53.3 | 43.7 | <.01 | 46.1 | 36.8 | <.01 |
| Female, % | 63.0 | 50.9 | <.01 | 54.5 | 62.0 | <.01 |
| Race/ethnicity, % | ||||||
| White | 31.5 | 46.7 | <.01 | 37.4 | 47.7 | <.01 |
| Black | 22.1 | 22.9 | .30 | 23.6 | 21.1 | <.01 |
| Hispanic | 44.9 | 29.0 | <.01 | 33.0 | 27.8 | <.01 |
| Other | 1.5 | 1.4 | .80 | 5.9 | 3.3 | <.01 |
| Comorbidityb, % | ||||||
| Dementia | 0.6 | 0.3 | <.01 | 0.1 | 0.0 | <.01 |
| Chronic pulmonary disease | 33.7 | 21.5 | <.01 | 19.3 | 11.9 | <.01 |
| Rheumatic disease | 2.4 | 2.1 | .13 | 1.2 | 0.7 | <.01 |
| Peptic ulcer disease | 1.3 | 0.7 | <.01 | 0.9 | 0.4 | <.01 |
| Hemiplegia | 0.9 | 1.0 | .49 | 0.3 | 0.1 | <.01 |
| Any malignancy | 6.9 | 4.7 | <.01 | 4.0 | 1.7 | <.01 |
| Mild liver disease | 4.0 | 2.2 | <.01 | 1.7 | 0.4 | <.01 |
| Moderate/severe liver disease | 1.9 | 0.8 | <.01 | 0.8 | 0.2 | <.01 |
| Metastatic tumor | 1.0 | 0.9 | .82 | 0.4 | 0.2 | <.01 |
| AIDS | 3.9 | 5.3 | <.01 | 0.9 | 0.6 | <.01 |
| Per capita medical expendituresc, $ | 29,026 | 24,438 | <.01 | 12,753 | 4,584 | <.01 |
| Florida | ||||||
| Sample, N | 12,990 | 57,345 | – | 2,370 | 60,318 | – |
| Mean age, y | 53.2 | 43.9 | <.01 | 41.2 | 31.8 | <.01 |
| Female, % | 62.4 | 51.5 | <.01 | 72.5 | 71.1 | .15 |
| Race/ethnicity, % | ||||||
| White | 38.7 | 46.7 | <.01 | 35.3 | 39.8 | <.01 |
| Black | 31.8 | 31.5 | .47 | 33.2 | 32.8 | .73 |
| Hispanic | 28.4 | 20.5 | <.01 | 30.3 | 26.3 | <.01 |
| Other | 1.1 | 1.4 | .01 | 1.2 | 1.1 | .61 |
| Comorbidityb, % | ||||||
| Dementia | 0.6 | 0.4 | <.01 | 0.0 | 0.0 | .44 |
| Chronic pulmonary disease | 35.2 | 20.2 | <.01 | 17.7 | 8.0 | <.01 |
| Rheumatic disease | 3.7 | 2.2 | <.01 | 1.4 | 0.7 | <.01 |
| Peptic ulcer disease | 2.2 | 1.0 | <.01 | 1.2 | 0.4 | <.01 |
| Hemiplegia | 1.2 | 1.3 | .82 | 0.3 | 0.1 | <.01 |
| Any malignancy | 12.4 | 6.7 | <.01 | 6.8 | 1.6 | <.01 |
| Mild liver disease | 3.0 | 1.5 | <.01 | 0.8 | 0.1 | <.01 |
| Moderate/severe liver disease | 1.2 | 0.6 | <.01 | 0.2 | 0.0 | <.01 |
| Metastatic tumor | 1.3 | 1.0 | <.01 | 0.9 | 0.2 | <.01 |
| AIDS | 5.3 | 7.7 | <.01 | 1.7 | 1.7 | .95 |
| Per capita medical expendituresc, $ | 23,367 | 16,250 | <.01 | 8,935 | 2,694 | <.01 |
| Illinois | ||||||
| Sample, N | 14,063 | 73,432 | – | 16,071 | 352,249 | – |
| Mean age, y | 53.2 | 43.7 | <.01 | 44.2 | 35.2 | <.01 |
| Female, % | 60.4 | 47.9 | <.01 | 64.6 | 76.3 | <.01 |
| Race/ethnicity, % | ||||||
| White | 37.2 | 37.0 | .60 | 41.8 | 52.7 | <.01 |
| Black | 48.5 | 52.8 | <.01 | 24.3 | 25.5 | <.01 |
| Hispanic | 12.3 | 8.8 | <.01 | 27.0 | 17.9 | <.01 |
| Other | 2.0 | 1.3 | <.01 | 7.0 | 3.9 | <.01 |
| Comorbidityb, % | ||||||
| Dementia | 0.5 | 0.2 | <.01 | 0.1 | 0.0 | <.01 |
| Chronic pulmonary disease | 38.3 | 21.7 | <.01 | 19.0 | 8.9 | <.01 |
| Rheumatic disease | 3.0 | 1.9 | <.01 | 1.4 | 0.7 | <.01 |
| Peptic ulcer disease | 2.8 | 1.5 | <.01 | 1.9 | 0.8 | <.01 |
| Hemiplegia | 1.7 | 1.4 | .03 | 0.4 | 0.1 | <.01 |
| Any malignancy | 13.2 | 7.5 | <.01 | 9.5 | 4.4 | <.01 |
| Mild liver disease | 2.6 | 1.3 | <.01 | 0.8 | 0.2 | <.01 |
| Moderate/severe liver disease | 1.1 | 0.5 | <.01 | 0.3 | 0.1 | <.01 |
| Metastatic tumor | 1.4 | 1.2 | .03 | 0.6 | 0.2 | <.01 |
| AIDS | 1.8 | 2.8 | <.01 | 0.3 | 0.2 | .08 |
| Per capita medical expendituresc, $ | 21,328 | 11,100 | <.01 | 8,085 | 2,077 | <.01 |
| Iowa | ||||||
| Sample, N | 2,769 | 13,879 | – | 935 | 40,994 | – |
| Mean age, y | 51.0 | 40.0 | <.01 | 39.3 | 36.3 | <.01 |
| Female, % | 67.3 | 53.2 | <.01 | 71.0 | 67.6 | .03 |
| Race/ethnicity, % | ||||||
| White | 83.7 | 84.7 | .18 | 74.5 | 81.7 | <.01 |
| Black | 11.8 | 11.6 | .80 | 13.6 | 10.7 | <.01 |
| Hispanic | 2.7 | 1.8 | <.01 | 8.1 | 4.2 | <.01 |
| Other | 1.8 | 1.9 | .91 | 3.7 | 3.3 | .46 |
| Comorbidityb, % | ||||||
| Dementia | 0.3 | 0.2 | .28 | 0.0 | 0.0 | .73 |
| Chronic pulmonary disease | 37.7 | 21.7 | <.01 | 24.1 | 6.9 | <.01 |
| Rheumatic disease | 2.3 | 1.4 | <.01 | 1.6 | 0.3 | <.01 |
| Peptic ulcer disease | 1.4 | 0.9 | <.01 | 1.4 | 0.2 | <.01 |
| Hemiplegia | 0.8 | 1.0 | .30 | 0.3 | 0.1 | <.01 |
| Any malignancy | 4.5 | 3.1 | <.01 | 2.7 | 0.6 | <.01 |
| Mild liver disease | 2.0 | 1.0 | <.01 | 1.3 | 0.1 | <.01 |
| Moderate/severe liver disease | 1.0 | 0.5 | <.01 | 0.6 | 0.0 | <.01 |
| Metastatic tumor | 0.8 | 0.8 | .82 | 0.4 | 0.1 | <.01 |
| AIDS | 0.3 | 0.3 | .99 | 0.2 | 0.1 | .48 |
| Per capita medical expendituresc, $ | 25,248 | 18,649 | <.01 | 11,912 | 2,318 | <.01 |
| New York | ||||||
| Sample, N | 5,111 | 36,073 | – | 1,200 | 25,951 | – |
| Mean age, y | 50.6 | 36.4 | <.01 | 46.1 | 34.1 | <.01 |
| Female, % | 57.3 | 43.6 | <.01 | 46.2 | 55.4 | <.01 |
| Race/ethnicity, % | ||||||
| White | 51.3 | 57.6 | <.01 | 51.5 | 58.2 | <.01 |
| Black | 25.0 | 23.4 | <.01 | 27.8 | 23.3 | <.01 |
| Hispanic | 20.4 | 15.5 | <.01 | 16.1 | 14.4 | .09 |
| Other | 3.2 | 3.5 | .34 | 4.7 | 4.1 | .34 |
| Comorbidityb, % | ||||||
| Dementia | 1.0 | 0.3 | <.01 | 0.0 | 0.0 | .52 |
| Chronic pulmonary disease | 32.0 | 13.2 | <.01 | 21.3 | 9.6 | <.01 |
| Rheumatic disease | 2.4 | 1.0 | <.01 | 0.8 | 0.5 | .18 |
| Peptic ulcer disease | 1.2 | 0.4 | <.01 | 0.9 | 0.5 | .03 |
| Hemiplegia | 2.1 | 1.5 | <.01 | 0.6 | 0.1 | <.01 |
| Any malignancy | 5.2 | 2.3 | <.01 | 8.1 | 3.4 | <.01 |
| Mild liver disease | 2.3 | 0.6 | <.01 | 1.9 | 0.5 | <.01 |
| Moderate/severe liver disease | 1.1 | 0.2 | <.01 | 1.3 | 0.1 | <.01 |
| Metastatic tumor | 0.9 | 0.4 | <.01 | 1.7 | 0.6 | <.01 |
| AIDS | 6.4 | 3.1 | <.01 | 3.9 | 1.8 | <.01 |
| Per capita medical expendituresc, $ | 57,501 | 48,127 | <.01 | 25,213 | 6,723 | <.01 |
| Oklahoma | ||||||
| Sample, N | 6,554 | 27,583 | – | 2,069 | 26,909 | – |
| Mean age, y | 51.6 | 43.1 | <.01 | 44.0 | 35.1 | <.01 |
| Female, % | 64.3 | 53.2 | <.01 | 69.6 | 74.3 | <.01 |
| Race/ethnicity, % | ||||||
| White | 64.7 | 68.0 | <.01 | 52.1 | 57.8 | <.01 |
| Black | 16.7 | 18.3 | <.01 | 11.5 | 11.8 | .68 |
| Hispanic | 4.1 | 3.1 | <.01 | 17.8 | 13.2 | <.01 |
| Other | 14.5 | 10.5 | <.01 | 18.6 | 17.2 | .12 |
| Comorbidityb, % | ||||||
| Dementia | 0.4 | 0.2 | <.01 | 0.0 | 0.0 | .36 |
| Chronic pulmonary disease | 37.4 | 24.7 | <.01 | 19.9 | 13.8 | <.01 |
| Rheumatic disease | 4.6 | 3.0 | <.01 | 2.4 | 1.7 | .03 |
| Peptic ulcer disease | 2.1 | 1.4 | <.01 | 1.1 | 0.9 | .35 |
| Hemiplegia | 1.9 | 1.4 | <.01 | 0.7 | 0.1 | <.01 |
| Any malignancy | 4.9 | 3.4 | <.01 | 5.4 | 2.4 | <.01 |
| Mild liver disease | 2.7 | 1.6 | <.01 | 1.2 | 0.4 | <.01 |
| Moderate/severe liver disease | 1.3 | 0.6 | <.01 | 0.5 | 0.1 | <.01 |
| Metastatic tumor | 0.9 | 0.9 | .69 | 1.0 | 0.4 | <.01 |
| AIDS | 0.3 | 0.7 | <.01 | 0.3 | 0.4 | .60 |
| Per capita medical expendituresc, $ | 20,276 | 12,284 | <.01 | 11,199 | 4,883 | <.01 |
P values are based on t test comparing means and χ2 test comparing proportions among people with and without diabetes.
Comorbidities are adapted from Deyo et al (15).
Unadjusted per capita mean annual medical expenditures (2012 US $).
Outcome variables
We estimated medical expenditures in total and by component (inpatient care, outpatient care, prescription drugs). Inpatient expenditures included claims for hospital stays, but generally did not include physician and other provider services (11). Outpatient expenditures included all services not included in the inpatient or prescription drug claims, such as physician and other provider services, home health care, transportation, and outpatient facilities (11). Prescription drug expenditures included claims for prescription drugs, durable medical equipment, and vaccines (11). Total expenditure was the sum of these 3 individual components.
Statistical analysis
For descriptive analyses, we calculated means for continuous variables and proportions for categorical variables, stratified by diabetes status. We tested the difference in means by using a t test and proportions by using a χ2 test between people with and without diabetes.
Not all enrollees had health care service use or medical expenditures during the year. In addition, expenditures were positively skewed for those who had expenditures. Therefore, we used a 2-part model to estimate inpatient care, outpatient care, and prescription drug expenditures by disability-based eligibility status (14). In the first part of the model, we used a generalized linear model with logit link and binomial distribution to estimate the probability of an individual having expenditures. In the second part, we used a generalized linear model with log link and gamma distribution to estimate medical expenditures.
In the models, we controlled for several covariates, including a dichotomously defined diabetes term (1 = diabetes diagnosis, 0 = without diabetes diagnosis). Choice of covariates was guided by past studies and data availability (8,12).The covariates included sex, age, age squared, race/ethnicity, and comorbidity indicators. Ten comorbidity indicators were included based on their prevalence (≥0.1%) and ICD-9-CM codes developed by Deyo et al (dementia, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, hemiplegia, any malignancy, mild liver disease, moderate/severe liver disease, metastatic tumor, and AIDS) (15).
We predicted individual-level annual mean medical expenditures by diabetes status with parameter estimates from the 2-part model and values of the covariates. The mean medical expenditures associated with diabetes were calculated as the difference in the predicted per capita annual mean medical expenditures between enrollees with and without diabetes. We also calculated the cost ratios between enrollees with and without diabetes by dividing the predicted mean expenditures of enrollees with diabetes by those without diabetes. We estimated standard errors of predicted and excess medical expenditures associated with diabetes by using the nonparametric bootstrapping method with 1,000 replicates. All statistical analyses were conducted in 2017 by using SAS Enterprise Guide 7.1 (SAS Institute).
Results
Table 1 reports characteristics and unadjusted total per capita medical expenditures for enrollees with and without diabetes by disability-based eligibility status. Among enrollees with disability-based eligibility, those with diabetes were more likely to be older, female, have larger proportions of diagnosed comorbidities, and have larger unadjusted total medical expenditures compared with those without diabetes. Characteristics of enrollees whose eligibility was not disability-based showed a similar pattern. The enrollees’ characteristics and unadjusted per capita total medical expenditures by disability and diabetes status displayed a similar pattern across the states.
Table 2 shows that, for disability-based enrollees, the estimated annual total excess medical expenditures associated with diabetes ranged from $6,183 (95% confidence interval [CI]: $5,627–$6,831) in Alabama to $15,319 (95% CI, $11,890–$19,023) in New York. Among enrollees with eligibility-based disability, those with diabetes spent 1.3 (New York) to 1.9 (California and Illinois) times more on total medical expenditures than those without diabetes (Table 2). In contrast, for nondisability enrollees, the estimated annual total excess medical expenditures associated with diabetes ranged from $4,985 (95% CI, $4,178–$5,912) in Alabama to $15,366 (95% CI, $12,100–$19,271) in New York (Table 2). The cost ratio ranged from 2.0 in Oklahoma to 3.3 in Iowa.
Table 2. Estimated Per Capita Mean and Excess Annual Total Medical Expenditures Among Adult Medicaid Enrollees Aged 19–64 Years by Disability-Based Eligibility and Diabetes Status, 8 States, 2012 .
| With disability |
Without disability |
||||||
|---|---|---|---|---|---|---|---|
| With diabetes Mean (95% CI), $ |
Without diabetes Mean (95% CI), $ |
Excessa
(95% CI), $ |
Ratiob | With diabetes Mean (95% CI), $ |
Without diabetes Mean (95% CI), $ |
Excessa
(95% CI), $ |
Ratiob |
| Alabama | |||||||
| 13,900 (13,336–14,599) | 7,717 (7,468–7,999) | 6,183 (5,627–6,831) | 1.8 | 9,530 (8,480–10,722) | 4,545 (4,070–5,125) | 4,985 (4,178–5,912) | 2.1 |
| California | |||||||
| 29,443 (27,969–31,112) | 15,890 (15,169–16,708) | 13,553 (12,061–15,288) | 1.9 | 12,727 (11,586–14,071) | 4,197 (3,804–4,641) | 8,530 (7,535–9,645) | 3.0 |
| Connecticut | |||||||
| 30,818 (29,231–32,656) | 19,631 (18,630–20,616) | 11,187 (9,446–13,043) | 1.6 | 14,901 (14,071–15,840) | 6,202 (5,883–6,537) | 8,699 (8,038–9,438) | 2.4 |
| Florida | |||||||
| 24,240 (23,471–25,274) | 15,810 (15,365–16,310) | 8,430 (7,610–9,381) | 1.5 | 11,227 (10,201–12,617) | 4,197 (3,837–4,581) | 7,030 (6,188–8,192) | 2.7 |
| Illinois | |||||||
| 22,925 (21,963–24,009) | 12,340 (11,887–12,805) | 10,585 (9,675–11,690) | 1.9 | 9,882 (9,269–10,615) | 3,433 (3,207–3,699) | 6,449 (5,966–7,060) | 2.9 |
| Iowa | |||||||
| 25,786 (24,166–27,784) | 16,060 (15,230–17,000) | 9,726 (8,179–11,641) | 1.6 | 13,269 (11,584–15,570) | 4,009 (3,431–4,601) | 9,260 (7,895–11,282) | 3.3 |
| New York | |||||||
| 60,520 (57,377–64,000) | 45,201 (43,487–46,912) | 15,319 (11,890–19,023) | 1.3 | 28,030 (24,147–32,363) | 12,664 (10,867–14,612) | 15,366 (12,100–19,271) | 2.2 |
| Oklahoma | |||||||
| 20,953 (19,910–22,193) | 12,555 (12,024–13,130) | 8,398 (7,359–9,619) | 1.7 | 12,490 (11,267–14,058) | 6,189 (5,637–6,796) | 6,301 (5,246–7,632) | 2.0 |
Excess: difference between mean estimated expenditures of enrollees with and without diabetes. All excess expenditures are statistically significant (P < .001).
Ratio: cost ratio of total medical expenditures of enrollees with diabetes to those without diabetes.
The composition of the excess total medical expenditures associated with diabetes is presented in Figure 1 for disability-based enrollees and Figure 2 for nondisability-based enrollees. Among disability-based enrollees in Alabama, Connecticut, Iowa, and Oklahoma, the largest share of expenditures was for outpatient care (46%, 45%, 39%, and 42%, respectively) (Figure 1). For California, Florida, and New York, the largest share was for prescription drugs (40%, 46%, and 37%, respectively). For Illinois, the largest share (37%) was for inpatient care. Among nondisability-based enrollees, for Alabama, California, Connecticut, Florida, and Illinois, prescription drugs accounted for the largest share (44%, 48%, 50%, 55%, and 45%, respectively) (Figure 2). For Iowa and Oklahoma, outpatient care had the largest share (39% and 43%, respectively). Finally, for New York, inpatient care had the largest share (45%).
Figure 1.
Percentage of inpatient care, outpatient care, and prescription drug expenditures of the total medical expenditures associated with diabetes among Medicaid adults with disability-based eligibility aged 19–64 years, 2012.
| State | Outpatient | Inpatient | Prescription Drug |
|---|---|---|---|
| Alabama | 46 | 17 | 37 |
| California | 30 | 30 | 40 |
| Connecticut | 45 | 16 | 39 |
| Florida | 23 | 30 | 46 |
| Illinois | 36 | 37 | 28 |
| Iowa | 39 | 23 | 38 |
| New York | 32 | 31 | 37 |
| Oklahoma | 42 | 33 | 25 |
Figure 2.
Percentage of inpatient care, outpatient care, and prescription drug expenditures of the total medical expenditures associated with diabetes among Medicaid adults without disability-based eligibility aged 19–64 years, 2012.
| State | Outpatient | Inpatient | Prescription Drug |
|---|---|---|---|
| Alabama | 37 | 19 | 44 |
| California | 31 | 21 | 48 |
| Connecticut | 34 | 16 | 50 |
| Florida | 30 | 15 | 55 |
| Illinois | 30 | 25 | 45 |
| Iowa | 39 | 23 | 38 |
| New York | 31 | 45 | 24 |
| Oklahoma | 43 | 25 | 32 |
Discussion
A previous study showed that the financial burden imposed by diabetes on state Medicaid programs was substantial (7). Our study also supported this conclusion. Our estimated cost ratios comparing enrollees with diabetes to those without diabetes are also within the range of a past research review, which found that the cost for people with diabetes was 1.5 to 4.4 times more than for those without diabetes (16). However, we showed that the per capita medical expenditures associated with diabetes varied greatly across states. The highest-spending state studied (New York) had per capita medical expenditures 3 times more than the lowest-spending state (Alabama). These variations in diabetes-associated medical expenditures imply that using estimates from national level data to monitor the financial burden of diabetes and inform Medicaid policy decision at the state level could be misleading.
Factors that contribute to the state variations in excess diabetes expenditures are complex, and identifying those reasons is beyond the scope of this study. However, we did decompose the total expenditure into service volume and payment per service by component (data not shown) to see how each of the 2 factors has contributed to the total excess expenditure. In general, high-expenditure states (California, Connecticut, and New York) tended to have higher payment per unit of service than low-expenditure states (Alabama, Florida, Illinois, Iowa, and Oklahoma), in particular for prescription drug fills. For example, for disability-based enrollees with diabetes, high-expenditure states paid 1.2 to 2.4 times more per prescription drug fill, on average, than low-expenditure states. However, it is less clear if high-expenditure states had a higher service volume per enrollee than low-expenditure states. The variation in medical expenditures could be explained in part by differences in eligibility criteria, benefits, and policies of state Medicaid programs (10). Other factors such as availability of state funding for public programs, access to care, availability of health services, and demand for services could have contributed to the variation (10).
Whether or not higher medical spending associated with diabetes leads to better diabetes care outcomes remains unclear, and is also beyond the scope of our study. Previous studies on this question showed that health care spending and the health status of people living in the state were not directly correlated (17). Other factors, such as economic stability, neighborhood environment, education, and healthcare systems (18), along with social services and public health spending (19), may play a more important role than per capita spending in determining overall health outcomes.
Our findings showed that medical expenditures associated with diabetes also varied by disability-based eligibility status. Those with disability-based eligibility had much higher absolute values of medical expenditure than those without disability-based eligibility (ranging from 1.4 to 2.3 times greater). In general, individuals with disability-based eligibility have a higher prevalence of chronic conditions, and therefore have higher medical expenditures than those without disability-based eligibility (20). In contrast, the cost ratios (between enrollees with diabetes and those without diabetes) among studied states for those with disability-based eligibility were much smaller (1.3–1.9) than those without disability-based eligibility (2.0–3.3). A similar pattern was observed by Shrestha and colleagues among youth by using MarketScan Medicaid data from 2008–2012. They showed that per capita annual diabetes-related medical expenditures were larger among youth with disability than those without disability ($9,944 vs $9,046), but the cost ratio for those with disability was much lower (1.7 vs 3.5) (21). This result may stem from the fact that individuals with disability-based eligibility already have numerous chronic conditions and incur high medical expenditures, so that having an additional condition (diabetes, in this case) creates less incremental financial burden than it does for those whose eligibility is not disability-based (22). The variation in diabetes-associated medical expenditures by eligibility criteria implies that medical needs differ for those with and without disability, requiring diverse interventions and strategies from stakeholders.
In addition, for disability-based enrollees, measured by cost ratios, diabetes imposed the largest burden in California and Illinois. But using absolute dollar amount as the measure, diabetes imposed the largest burden in New York (Table 2). For nondisability-based enrollees, Iowa had the largest diabetes burden if cost ratio were used and New York had the largest burden if absolute dollar amount were used (Table 2). Thus, both absolute and relative differences in estimated medical expenditures between those diagnosed with diabetes and without diabetes are important measures to better understand the financial burden of diabetes in the Medicaid population.
Our results also showed that the proportion of components in total medical expenditures differed by state and eligibility criteria. This could be explained in part by the differences in coverage benefits, reimbursements, and cost-sharing policies of state Medicaid programs (23,24). Among 4 states (Alabama, Connecticut, Iowa, and Oklahoma) that had average physician fees greater than the Medicaid national average, outpatient care expenditures accounted for a larger share of excess total medical expenditures (data not shown).
For inpatient care policies, New York was the only studied state that required no prior approval for inpatient hospital services, imposed no limit on number of service days, and had higher than national average payment per inpatient hospital stay. Historically, New York has tended to offer many optional services and paid much higher hospital fees than many other states (25), which might explain why its inpatient expenditures accounted for a higher share of total diabetes-related medical expenditures.
As for prescription drug policies, such as prior authorization requirement, copayment, and monthly limit on prescription drugs, no clear picture emerged to explain the variation of composition in total diabetes excess expenditures. Prior research suggests the reason for the largest share of prescription drug expenditures could be due mainly to higher volume and prescription drug prices (newer and more expensive drugs) used to treat diabetes or diabetes-related complications (or due to health behavior needs) (8). In addition, more and better use of disease management services at outpatient or primary care settings could have resulted in greater prescription utilization and adherence (26).
Studies have shown that type 2 diabetes is preventable through prevention efforts such as the National Diabetes Prevention Program, a structured lifestyle change program, and could potentially reduce the financial burdens of state Medicaid programs (27). This program has been found to reduce the risk of type 2 diabetes by more than half and to be cost-effective (28). For those with diabetes, disease management is critical to prevent diabetes-related complications. Diabetes self-management education and support (DSMES) provides support for informed decision-making and self-care practices, and could improve health outcomes and reduce the financial burdens of state Medicaid programs (29). DSMES has been shown to reduce risk of diabetes complications and to be cost-effective (30).
Limitations
Our study has several limitations. First, we focused on FFS enrollees; therefore, the results may not apply to the Medicaid population enrolled in other insurance programs. Second, our findings may not be applicable to other states, owing to the heterogeneity of state Medicaid programs and population characteristics. Third, medical expenditures for type 1 and type 2 diabetes are different, but limitations of coding from administrative claims data and the nature of the treatment schemes prevented us from reliably distinguishing them. However, because most adults have type 2 diabetes, these results likely primarily reflect medical expenditures associated with type 2 diabetes than type1 diabetes. Fourth, the cost of a chronic condition that was estimated by using claims data may depend on the specific algorithm used for identifying people with that condition. Thus, our estimated cost of diabetes might differ if we used another algorithm to identify those with diabetes. Finally, no out-of-pocket costs or indirect costs were available, which would have provided a broader perspective of financial burden associated with diagnosed diabetes.
Because states have options in setting Medicaid policies, variations in eligibility criteria and specific benefit coverage across states could result in different diabetes-associated medical expenditures. Past studies on these expenditures in the Medicaid population mainly focused on national-level estimates. State-specific estimates were either not available or were extrapolated from national data. Our estimates for state-level diabetes-associated medical expenditures can be used by the 8 state Medicaid programs to prepare healthcare resources needed for diabetes care and to assess the financial benefits of diabetes prevention and management programs.
Acknowledgments
The authors thank Clarice Conley of the Division of Diabetes Translation at the Centers for Disease Control and Prevention for her editorial assistance.
No financial support was provided for this project.
No copyrighted material, surveys, instruments, or tools were used.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Footnotes
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.
Suggested citation for this article: Ng BP, Shrestha SS, Lanza A, Smith B, Zhang P. Medical Expenditures Associated With Diabetes Among Adult Medicaid Enrollees in Eight States. Prev Chronic Dis 2018;15:180148. DOI: https://doi.org/10.5888/pcd15.180148.
References
- 1. Centers for Medicare & Medicaid Services. 2012. CMS statistics. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Statistics-Reference-Booklet/2012.html. Accessed June 06, 2017.
- 2. Rabi DM, Edwards AL, Southern DA, Svenson LW, Sargious PM, Norton P, et al. Association of socio-economic status with diabetes prevalence and utilization of diabetes care services. BMC Health Serv Res 2006;6(1):124. 10.1186/1472-6963-6-124 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Kaiser Family Foundation. The role of Medicaid for people with diabetes. https://kaiserfamilyfoundation.files.wordpress.com/2013/01/8383_d.pdf. Accessed June 21, 2017.
- 4. Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat 10 2014;Feb(260):1–161. [PubMed] [Google Scholar]
- 5. Centers for Disease Control and Prevention. Diabetes State Burden Toolkit. 2017. https://nccd.cdc.gov/Toolkit/DiabetesBurden/MedicalCost/ByPayer. Accessed June 17, 2017.
- 6. Centers for Disease Control and Prevention. Diabetes Report Card 2014. https://www.cdc.gov/diabetes/library/reports/reportcard.html. Accessed June 17, 2017.
- 7. Garfield RL, Damico A. Medicaid expansion under health reform may increase service use and improve access for low-income adults with diabetes. Health Aff (Millwood) 2012;31(1):159–67. 10.1377/hlthaff.2011.0903 [DOI] [PubMed] [Google Scholar]
- 8. Zhuo X, Zhang P, Kahn HS, Bardenheier BH, Li R, Gregg EW. Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care 2015;38(4):581–7. 10.2337/dc14-1687 [DOI] [PubMed] [Google Scholar]
- 9. Huang ES, Basu A, O’Grady MJ, Capretta JC. Using clinical information to project federal health care spending. Health Aff (Millwood) 2009;28(5):w978–90. 10.1377/hlthaff.28.5.w978 [DOI] [PubMed] [Google Scholar]
- 10. Young K, Rudowitz R, Rouhani S, Garfield R. Medicaid per enrollee spending: variation across states. http://www.kff.org/medicaid/issue-brief/medicaid-per-enrollee-spending-variation-across-states/. Accessed July 1, 2017.
- 11. Ruttner L, Borck R, Nysenbaum J, Williams S. Guide to MAX data. https://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-Systems/MedicaidDataSourcesGenInfo/Downloads/MAX_IB21_MAX_Data_Guide.pdf. Accessed March 6, 2017.
- 12. Shrestha SS, Zhang P, Li R, Thompson TJ, Chapman DP, Barker L. Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008. Diabetes Res Clin Pract 2013;100(1):102–10. 10.1016/j.diabres.2013.02.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Medicaid Analytic eXtract (MAX) General Information. https://www.cms.gov/research-statistics-data-and-systems/computer-data-and-systems/medicaiddatasourcesgeninfo/maxgeneralinformation.html. Accessed October 20, 2017.
- 14. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ 2004;23(3):525–42. 10.1016/j.jhealeco.2003.10.005 [DOI] [PubMed] [Google Scholar]
- 15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613–9. 10.1016/0895-4356(92)90133-8 [DOI] [PubMed] [Google Scholar]
- 16. Ng CS, Lee JY, Toh MP, Ko Y. Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes Res Clin Pract 2014;105(2):151–63. 10.1016/j.diabres.2014.03.020 [DOI] [PubMed] [Google Scholar]
- 17. The Pew Charitable Trusts. Providing context for state health care spending. http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/health-indicators. Accessed May 22, 2017.
- 18. Kaiser Family Foundation. Beyond health care: the role of social determinants in promoting health and health equity. http://www.kff.org/disparities-policy/issue-brief/beyond-health-care-the-role-of-social-determinants-in-promoting-health-and-health-equity/. Accessed May 19, 2017.
- 19. Bradley EH, Canavan M, Rogan E, Talbert-Slagle K, Ndumele C, Taylor L, et al. Variation in health outcomes: the role of spending on social services, public health, and health care, 2000-09. Health Aff (Millwood) 2016;35(5):760–8. 10.1377/hlthaff.2015.0814 [DOI] [PubMed] [Google Scholar]
- 20. Mitra S, Findley PA, Sambamoorthi U. Health care expenditures of living with a disability: total expenditures, out-of-pocket expenses, and burden, 1996 to 2004. Arch Phys Med Rehabil 2009;90(9):1532–40. 10.1016/j.apmr.2009.02.020 [DOI] [PubMed] [Google Scholar]
- 21. Shrestha SS, Zhang P, Thompson TJ, Gregg EW, Albright A, Imperatore G. Medical expenditures associated with diabetes among youth with Medicaid coverage. Med Care 2017;55(7):646–53. 10.1097/MLR.0000000000000725 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Pumkam C, Probst JC, Bennett KJ, Hardin J, Xirasagar S. Health care expenditures among working-age adults with physical disabilities: variations by disability spans. Disabil Health J 2013;6(4):287–96. 10.1016/j.dhjo.2013.03.002 [DOI] [PubMed] [Google Scholar]
- 23. Halpern MT, Romaire MA, Haber SG, Tangka FK, Sabatino SA, Howard DH. Impact of state-specific Medicaid reimbursement and eligibility policies on receipt of cancer screening. Cancer 2014;120(19):3016–24. 10.1002/cncr.28704 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Polsky D, Richards M, Basseyn S, Wissoker D, Kenney GM, Zuckerman S, et al. Appointment availability after increases in Medicaid payments for primary care. N Engl J Med 2015;372(6):537–45. 10.1056/NEJMsa1413299 [DOI] [PubMed] [Google Scholar]
- 25. Rodin D, Meyer J. Health care costs and spending in New York State. New York (NY): NYS Health Foundation, 2014. [Google Scholar]
- 26. Freeman R, Lybecker KM, Taylor DW. The effectiveness of disease management programs in the Medicaid population. Hamilton (ON): The Cameron Institute, 2011. [Google Scholar]
- 27. Centers for Disease Control and Prevention. National Diabetes Prevention Program. https://www.cdc.gov/diabetes/prevention/prediabetes-type2/preventing.html. Accessed June 25, 2017.
- 28. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374(9702):1677–86. 10.1016/S0140-6736(09)61457-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Hess-Fischl A, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. J Acad Nutr Diet 2015;115(8):1323–34. 10.1016/j.jand.2015.05.012 [DOI] [PubMed] [Google Scholar]
- 30. Brown HS 3d, Wilson KJ, Pagán JA, Arcari CM, Martinez M, Smith K, et al. Cost-effectiveness analysis of a community health worker intervention for low-income Hispanic adults with diabetes. Prev Chronic Dis 2012;9:E140. 10.5888/pcd9.120074 [DOI] [PMC free article] [PubMed] [Google Scholar]